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expressed in a significant number of the
uterine cervical carcinomas
Opal L. Reddy, Peter I. Shintaku and Neda A. Moatamed*Abstract
Background: The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has
emerged as a promising new target for cancer therapeutics, with lasting responses seen in the treatment of
metastatic renal and lung carcinomas, as well as melanomas. As tumor surface expression of PD-L1 has been found
to correlate with objective responses to anti-PD-L1 immunotherapies, we investigated the expression of PD-L1 in
human cervical tumors and provide an adopted scoring system for the systematic evaluation of PD-L1 staining.
Methods: Immunohistochemical staining for PD-L1 expression was performed on a tissue microarray of 101 normal
and neoplastic cervical tissues. Neoplastic cores were divided into three groups: squamous cell carcinoma,
adenosquamous carcinoma, and endocervical adenocarcinoma. PD-L1 expression was scored based on an adopted
scoring system accounting to percentage and intensity of positivity, and results provided alongside available clinical
and demographic data.
Results: Overall, PD-L1 was positive in 32 of 93 (34.4%) cervical carcinomas. Subcategorically, PD-L1 was positive in
28 of 74 (37.8%) squamous cell carcinomas, two of seven (28.6%) adenosquamous carcinomas, and two of 12 (16.
7%) endocervical adenocarcinomas. It was negative in six benign cervical tissues.
Conclusions: This study shows a significant expression of PD-L1 in 34.4% of cervical carcinomas and no expression
of PD-L1 in benign cervical tissues. These findings suggest a role for further investigation of anti-PD-L1/PD-1
immunotherapies in the treatment of PD-L1-positive cervical tumors. In addition, our adopted scoring system will
facilitate more systematic correlations between tumor reactivity and response to treatment.
Keywords: Uterine cervix, Cervical cancer, Squamous cell carcinoma, Endocervical adenocarcinoma,
Adenosquamous carcinoma, PD-L1, Immunohistochemistry, Immunotherapy, Tissue microarrayThis work was presented at the annual meeting of the
United States and Canadian Academy of Pathology
(USCAP) in Seattle Washington on March 14, 2016 [1].Background
Cancer of the uterine cervix is the third most common gy-
necologic cancer in the United States, with approximately
13,000 new cases and 4120 cancer deaths estimated to
occur in 2016 [2]. Persistent human papillomavirus (HPV)
infection, particularly with HPV16, HPV18, and other* Correspondence: nmoatamed@mednet.ucla.edu
Department of Pathology and Laboratory Medicine, David Geffen School of
Medicine at UCLA, 10833 Le Conte Avenue, BOX 951732, 1P-241 CHS, Los
Angeles, CA 90095-1732, USA
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(http://creativecommons.org/publicdomain/zehigh risk types, plays a key role in the development of
cervical cancer. While screening measures for cervical
dysplasia have decreased the incidence of cervical cancer
in the United States, cervical cancer remains a major
world health problem for women [3, 4]. Depending on the
disease stage, treatment for cervical cancer may involve a
combination of hysterectomy, pelvic lymph node dissec-
tion, and chemoradiation. Targeted therapies using small
molecules or monoclonal antibodies are largely still in
clinical trial stages [4].
PD-1 is an immune suppressive molecule in the B7-
CD28 family that regulates T-cell activation [5]. PD-L1 is
a transmembrane protein that can be expressed on tumor
cells in the cancerous microenvironment [6]. PD-L1 hasle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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downregulate anti-tumor T-cell activity and facilitate
immune evasion [7]. Expression of PD-L1 has also been
found to be associated with worse survival in solid tumors,
including esophageal, gastric, colorectal cancers, and
pulmonary adenocarcinoma [8, 9].
The PD-1/PD-L1 axis has emerged as a promising new
target for immune checkpoint therapies. Lasting responses
have been seen with anti-PD-L1 antibodies in the treat-
ment of metastatic renal and lung carcinomas, as well as
melanomas [7]. Currently, there are also ongoing clinical
phase I/II trials evaluating the effects of anti-PD-1 therap-
ies, including pembrolizumab (NCT02054806) and nivo-
lumab (NCT02488759), against advanced cervical cancer,
though no study results have been reported [10]. Tumor
surface expression of PD-L1 has been found to correlate
with objective responses to anti-PD-L1 immunotherapies,
and provide a rationale for screening tumor samples to
identify candidates for these targeted therapies [11]. As
data is still lacking on the expression patterns of PD-L1 in
benign and malignant cervical tissues, we investigated the
expression of PD-L1 in human cervical tissue and cervical
tumors on tissue microarrays. Our findings provide ra-
tionale for further investigation of PD-L1 immunother-
apies in the treatment of cervical cancer. Since, currently
there is no unified scoring system for PD-L1 expression
by immunohistochemistry as opposed to Her2/neu [12],
we are introducing a scoring algorithm which is based on
the work published by Garon et al. [13].
Methods
This study was approved by the Office of the Research
Protection Program at University of California, Los Angeles
(IRB# 15-001035-CR-00001).
Tissue microarray
We obtained glass slides of human formalin-fixed paraf-
fin embedded cervical tissue microarray (TMA) from
Abcam Inc. (Cambridge, MA) [14]. The TMA included
approximately 100 cores of both normal and neoplasticFig. 1 Intensities of the PD-L1 reactions (objective 60×). a Intensity 0, show
weak and/or incomplete circumferential cell membrane reactions (#16, Tab
membrane staining (#7, Table 1). d Intensity 3+, showing very strong circumcervical tissues. Hematoxylin and eosin staining was per-
formed on one slide for histopathology evaluation. Diag-
noses of the cores were reevaluated by one of the
authors (NAM), a gynecopathologist, for diagnostic and
grading accuracy. Histopathologic diagnoses were made
per established criteria and nomenclature [15–17]. Per
the Abcam specifications, all tissues were fixed in 10%
neutral buffered formalin for 24 h and processed using
identical standard operating procedures. Sections were
freshly cut upon order and placed on Superfrost-Plus or
Starfrost adhesive slides [14]. Upon examination, the
sections were consistent with 4–6 μm in thickness.
Immunohistochemical staining and intensity
Rabbit anti-human PD-L1 monoclonal antibody (clone
SP142) was obtained from Spring Bioscience (Pleasan-
ton, CA) [18]. Ventana Medical Systems, Inc. (Tucson,
AZ) has based its assay on this clone [19]. Immunohisto-
chemistry (IHC) was carried out on one of the TMA
slides employing the anti-PD-L1 antibody at a 1:100 di-
lution, adhering to the general guidelines recommended
by the Spring Bioscience protocol [18]. Appropriate
positive and negative controls were included. The results
were recorded based on the intensity of the staining re-
action on the cell membranes as described below (Fig. 1),
as well as the estimated percentage of positive tumor
cells. Positive non-epithelial cells as well as cytoplasmic
reactions were discounted.
Intensity 0: If there was no reaction on the cell
membranes (Fig. 1a).
Intensity 1+: If the reaction was barely visible or was
partially circumferential (Fig. 1b).
Intensity 2+: If the reaction was clearly visible and was
completely circumferential (Fig. 1c).
Intensity 3+: If the reaction was intense and fully
circumferential (Fig. 1d).
Statistical analysis
Statistical analysis was performed using a 2 × 2 table for
nonparametric Fisher Exact testing. A two-sided p-valueing no cell membrane reaction (#8, Table 2). b Intensity 1+, showing
le 2). c Intensity 2+, showing distinct complete circumferential cell
ferential cell membrane reaction (#47, Table 2)
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between the two compared sets of data. Office-365 Excel
(Microsoft, Redmond, WA) and Statistica (version 12;
StatSoft Inc, Tulsa, OK) were used for tabulation of data
and the statistical analyses [20].
Study design
A PD-L1 scoring scheme was adopted from Garon et al.
for anti-PD-1 treatment in non-small cell lung carcinomas
(NSCLC) [13]. Based on their protocol developed during
the initial trial phase, all lung tumor biopsies with 50% or
more cells showing the PD-L1 reaction, regardless of the
intensity, were considered as “positive” for the immuno-
therapy purposes as it is a practice in our institution [13].
In our adopted scoring system, we evaluated the non-
necrotic cells in normal and neoplastic tissues resulting in
three categories, “Negative”, “Low-Positive (LoPos)”, and
“Positive” as defined in the scoring scheme below:
Score “0”–Positive cells: 0%; Intensity: 0; Interpretation:
Negative.
Score “1a”–Positive cells: <50%; Intensity: 1+,
Interpretation: Low-Positive.
Score “1b”–Positive cells: <50%; Intensity: 2+ and/or 3
+; Interpretation: Low-Positive.
Score “2a”–Positive cells: ≥50%; Intensity: 1+;
Interpretation: Positive.
Score “2b”–Positive cells: ≥50%; Intensity: 2+ and/or 3
+; Interpretation: Positive.
If all cells had no PD-L1 reaction, a score of “0” and the
interpretation of “Negative” were assigned. If 50% or more
of the cells had the PD-L1 reactions, a score of “2” and the
interpretation of “Positive” was given. The “Positive” inter-
pretation had two subsets, “2a” if the intensity was 1+ and
“2b” if the intensity was either 2+ or 3+ (see above). If
there was ≥1% but <50% cellular reactivity a score of “1”
and an interpretation of “Low-Positive” were assigned with
two subsets of “1a” and “1b”. Similar to the “Positive”
interpretation, “1a” and “1b” scorings were for 1+, and 2+
or 3+ intensities respectively.
Based on the histopathological diagnoses, the core sam-
ples were divided into three groups: Group I, squamous
cell carcinoma; Group II, adenosquamous carcinoma; and
Group III, endocervical adenocarcinoma. Using the
designed scoring method, PD-L1 expression findings were
recorded for each group & subgroup and tabulated in their
respective tables. The available corresponding clinical and
demographic information was extracted from the Abcam
product booklet and added alongside the findings [14].
Results
Of the 101 cores of uterine cervical tissues on the TMA
slide, two were excluded for technical issues of beingpartially or completely washed off during the staining
procedures. Six of the cores were benign, with three
normal cervical samples and three cervical tissues with
cervicitis. All the six benign cervical samples were
histopathologically verified and interpreted as “Negative”
for PD-L1 expression. The remaining 93 cores were
carcinomas, sampled from a patient population with a
median age of 44 years. Thirty-two (34.4%) of these
samples were “Positive” and 25 (26.9%) were “Negative”
for the PD-L1 reactivity. In addition, twelve (12.9%) cores
had 1+ (“LoPos, 1a”) reactivity and Twenty-four (25.8%)
cores had 2+ or 3+ (“LoPos, 1b”) reactivity for PD-L1 in
less than 50% of the tumor cells, a total of 38.7%.
Group I, squamous cell carcinoma
Of the 93 cores, 74 were squamous cell carcinomas (SCCs).
The patients’ median age was 44.5 years old. Among these
tumors, 28 were “Positive” for the PD-L1 reactions. This
group was further divided into three subgroups based on
the histopathological grading of the tumors.
Subgroup IA, SCC Grade-I
This subgroup comprised of seven core samples with pa-
tients’ ages ranging from 37 to 68, with a median of
46 years old. Three (42.9%) of the cases had “Positive”
PD-L1 expression, all with the score of “2b”. There were
one “Negative”, one “LoPos, 1a”, and two “LoPos, 1b”
cores constituting the remaining four (Table 1).
Subgroup IB, SCC Grade-II
This subgroup comprised of 52 core samples with
patients’ ages ranging from 30 to 67 with a median of
44.5 years old. Twenty-four (46.2%) of the cases had
“Positive” PD-L1 expression, four with the score of “2a”
and 20 with the score of “2b”. The rest were nine “Nega-
tive,” eight “LoPos, 1a”, and 11 “LoPos, 1b” cores (Table 2).
An example of grade-II squamous cell carcinoma with the
corresponding positive PD-L1 stain is shown in Fig. 2.
Subgroup IC, SCC Grade-III
This subgroup comprised of 15 core samples with patients’
ages ranging from 30 to 59, with a median of 39 years old.
One (6.7%) case had “Positive” PD-L1 expression with the
score of “2b”. The remainder showed six “Negative”, one
“LoPos, 1a”, and seven “LoPos, 1b” samples (Table 3).
Group II, adenosquamous carcinoma
This group comprised of seven core samples with patients’
ages ranging from 27 to 56, with a median of 44 years old.
Two (28.6%) cases had “Positive” PD-L1 expression, one with
the score of “2a” and the other with score of “2b”. Remaining
five included four “Negative” and one “LoPos, 1b” cores
(Table 4). An example of adenosquamous carcinoma with
the corresponding positive PD-L1 stain is shown in Fig. 3.
Table 1 Subgroup IA, summary of cases with grade-I squamous cell carcinoma and tumor cell PD-L1 scoring as described in this study
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This group comprised of 12 core samples with patients’
ages ranging from 24 to 50, with a median of 39.5 years
old. Two (16.7%) cases had “Positive” PD-L1 expression,
one with the score of “2a” and another with a score of
“2b”. Remaining ten contained four “Negative”, two
“LoPos, 1a”, and three “LoPos, 1b” samples (Table 5). An
example of endocervical adenocarcinoma with the corre-
sponding positive PD-L1 stain is shown in Fig. 4.
The findings in the above groups are summarized in
Table 6 and show a propensity of “Positive” reaction
among squamous cell carcinomas, though, the positivity
ranged from 6.7% in grade-III SCC to more than 40% in
grade-I and grade-II SCCs. Endocervical adenocarcinomas
had the lowest positivity (16.7%) among the three groups.
There was no difference between grade-I and grade-II
SCCs (p-Value = 1), namely the two subgroups were
virtually identical (Table 6), therefore lumped together for
further analyses. The Fisher Exact statistical analysis
yielded a p-value of 0.0062 when lower grades (grade I &
II) SCCs were tested against high grade (grade III) SCCs
(Table 6). When SCCs (all grades) were tested against
adenosquamous carcinomas and endocervical adenocar-
cinomas, p-values of 1 and 0.2 were obtained respectively,
indicating no statistical differences (Table 6). Even, when
the high grade (grade III) SCCs were excluded from the
comparison lists, adenosquamous carcinomas and endo-
cervical adenocarcinomas maintained a statistically insig-
nificant difference (p-Values of 0.4 & 0.1 respectively) with
lower grades SCCs (Table 6).
Discussions
This study was carried out on a TMA which is made of
small size samples. Due to heterogeneity of the PD-L1
reactions, some of the negative samples may have been
randomly selected from the “negative” portion ofotherwise “positive” tumors. The small size of the TMA
samples, however, may mimic the size of the needle bi-
opsy specimens obtained in advanced cancer cases
which may have similar PD-L1 reaction outcome. The
results of the current study provide a baseline informa-
tion for the future investigations.
Since there is no unified scoring system for the PD-L1
reactions by IHC, the scoring introduced in this study is
based on the Garon et al. NSCLC study [13]. using the
antibody clone 22c3 which is used in the Dako platform
[21]. In this platform, the cutoff point is set at 50% for
the positive cells regardless of the intensity of the reaction.
The Ventana platform, based on clone SP142, uses 5% cut-
off for positivity, again regardless of the intensity [19]. Food
and Drug Administration (FDA) has approved both plat-
forms. Other investigators have used different scoring
schemes. In a recently published study, the investigators
have used different cutoff points for different immunother-
apeutic agents, regardless of the intensity, as listed in the
supplemental eTable 3 embedded with their publication
[22]. This pathology scoring system faces an issue. As new
therapeutic agents are introduced and/or future clinical
studies result in changes of the response rates, the scoring
system needs to be accordingly adjusted. Therefore, a path-
ology scoring system is needed for a comprehensive and
consistent evaluation of the PD-L1 reactions. Thus, it be-
comes incumbent upon the clinical oncologist to adjust
their protocols as new therapeutic agents are introduced or
therapeutic outcomes are changed. The pathologists, how-
ever, may amend their scoring reports with comments to
include the current rates of the positivity in relation to re-
sponses to various immunotherapeutic agents. Although,
the 50% cutoff for positivity is employed in this study, the
variable rates are also incorporated as “Low-Positive” if less
than 50% positive cells are encountered. In this study, we
have treated the “Low-Positive” samples as “Negative” for
Table 2 Subgroup IB, summary of cases with grade-II squamous cell carcinoma and tumor cell PD-L1 scoring as described in this study
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reactions is retained as a component of the scoring system
for future evaluations.At the outset, PD-L1 is “positively” expressed in more
than 34% of the uterine cervical carcinomas based on the
proposed scoring. Its highest expression appears in
Fig. 2 Score 2 in squamous cell carcinoma. An example of Score 2b in grade-II squamous cell carcinoma of the cervix showing PD-L1 staining of
100% of the tumor cells (#49, Table 2). a shows hematoxylin and eosin stain of the carcinoma with moderate differentiation containing a mitotic
figure at the center of the photomicrograph (objective 40×). b demonstrates the intense membrane reaction for PD-L1 with 3+ intensity involving
all tumor cells (objective 40×)
Reddy et al. Diagnostic Pathology  (2017) 12:45 Page 6 of 11squamous cell carcinomas although it is significantly lower
in the high grade (grade-III) SCCs (Table 6). While the per-
centages of the “Positive” PD-L1 expression in adenosqua-
mous carcinomas (~29%) and endocervical carcinomas
(~17%) are lower than SCCs (~38%), the differences are not
statistically significant (Table 6). In other words, PD-L1 is
highly expressed in the uterine cervical carcinomas except
for the high grade SCC. In all, more than 34% of theTable 3 Subgroup IC, summary of cases with grade-III squamous cellpatients with uterine cervical cancers may become clinically
eligible for the immunotherapy. In addition, about 39% of
the patients, in “LoPos, 1a” and “LoPos, 1b” categories may
also be considered for the therapy, though a smaller per-
centage of such cases may respond to the targeted therapy
as it has been noted in the NSCLC clinical trial [13].
Therapeutic targeting of the PD-1/PD-L1 immune regu-
latory axis has led to meaningful results in the treatmentcarcinoma and tumor cell PD-L1 scoring as described in this study
Table 4 Group II, summary of cases with adenosquamous carcinoma and tumor cell PD-L1 reactions with the final scoring as
described in this study
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cinoma, NSCLC, and head & neck squamous cell carcin-
oma [7]. For the treatment of advanced cervical cancer,
there are also ongoing clinical phase I/II trials evaluating
the effects of anti-PD-1 therapies, including pembrolizu-
mab (NCT02054806) and nivolumab (NCT02488759), al-
though study results have not yet been reported [10].
While data on the use of PD-L1 tumor expression as a
screening marker to identify patients for anti-PD-L1 im-
munotherapies have been conflicting, several studies have
found positive correlations between tumor expression of
PD-L1 and response to the targeted therapies [11, 23].
Though the use of anti-PD-1/PD-L1 immunotherapies
has not been extensively explored for the treatment of
cervical cancer, recent studies have evaluated biologic
rationales for PD-L1 expression in the cervical tumors,
including its pathogenesis through human papillomavirus
(HPV), its tumor microenvironment composed of tumor-Fig. 3 Score 2 in adenosquamous carcinoma. An example of Score 2b ade
the tumor cells (#6, Table 4). a shows hematoxylin & eosin stain of the glan
center of the glandular structures contains solid nests of cells with squamo
staining of all tumor cells (objective 10×). c shows complete circumferentia
40×). This intensity may be interpreted as 3+ by some other pathologistsinfiltrating lymphocytes, as well as its genetic basis for
increased expression.
Human papilloma virus (HPV) plays a key role in the
development of the two most common histologic subtypes
of cervical cancer, SCC and endocervical adenocarcinoma.
In particular, HPV16 has been linked to 59 and 36%, and
HPV18 to 13 and 37%, of SCC and the adenocarcinoma,
respectively [24]. The two histologic subtypes have also
been found to demonstrate distinct molecular profiles,
though current treatment guidelines are generally not
type-specific [25]. Some studies have speculated that HPV
may activate PD-1/PD-L1 immunosuppression to evade
host immune responses against the virus, resulting in per-
sistence and recurrence of cervical intraepithelial neopla-
sia (CIN) [26]. A recent study by Mezache et al. examined
PD-L1 expression in CIN and cervical SCC, and found
PD-L1 expression to be strongly associated with HPV in-
fection. In their study, PD-L1 was also upregulated in bothnosquamous carcinoma showing the PD-L1 reaction involving 100% of
dular organization of the tumor cells with adjacent stromal tissue. The
id differentiation (objective 20×). b demonstrates the PD-L1 membrane
l cell membrane staining of the tumor cells with 2+ intensity (objective
Table 5 Group III, summary of cases with endocervical adenocarcinoma and tumor cell PD-L1 reactions with the final scoring as
described in this study
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cells mostly CD8+ lymphocytes [27].
While the current study has evaluated PD-L1 expres-
sion of the tumor cells, it is unclear whether PD-L1 ex-
pression in tumor-infiltrating inflammatory cells also
plays a relevant role in predicting response to anti-PD-
L1 therapies [23]. Indeed, some studies have suggested
that PD-1/PD-L1 expression in the tumor microenviron-
ment may be important for therapeutic activity [5, 23].Fig. 4 Score 2 in endocervical adenocarcinoma. An example of Score 2b end
90% of the epithelial tumor cells (#12, Table 5). a shows the hematoxylin & eo
inflammatory stromal core (objective 20×). b demonstrates the membrane re
many at cross section (objective 10×). The inset shows the circumferential me
(objective 60×)The tumor microenvironment of cervical cancers has
been well-studied, with some studies demonstrating the
presence of tumor-infiltrating lymphocytes (TILs), and
particularly CD8+ T-cells, to be strongly associated with
improved clinical outcome and prognosis [28, 29]. A
study by Karim et al. found PD-L1 to be expressed in
only 19% of cervical cancers, whereas more than half of
tumor-infiltrating CD8+ T-cells were positive for PD-1
[30]. Differences in expression from their study may be aocervical adenocarcinoma of the cervix with PD-L1 reaction involving
sin stain of the glandular structures with atypical epithelial cell lining and
action for PD-L1 with 2+ intensity involving the epithelial tumor cells,
mbrane staining of the tumor cells for PD-L1 at a higher magnification
Table 6 Summary of the cases with Score-3 PD-L1 positivity in the different groups and subgroups of the uterine cervical carcinomas
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Yang et al. also evaluated PD-1 and PD-L1 expression
on cervical T-cells and dendritic cells, respectively, and
found their upregulation to be associated with high risk-
HPV positivity and increasing CIN grade [31]. Together,
these findings suggest a strong immunopathogenic ra-
tionale for PD-L1 expression in cervical carcinomas.
Several studies have explored a genetic basis for PD-L1
expression in various cancers, as well as its correlation with
clinical outcome. In particular, PD-L1 amplification anddeletion has been found to be associated with poor overall
survival amongst many major cancer types [32]. Overex-
pression of PD-L1 by immunohistochemical methods has
also been found to be associated with worse survival in
solid tumors, including esophageal cancer, gastric cancer,
colorectal cancer, and pulmonary adenocarcinoma [8, 9].
Ironically, a higher percentage of the reaction has occurred
in the lower grade carcinomas in this study. This finding
may be due to a lower sample size of grade III SCCs in this
series and/or the scoring which has excluded the “Low-
Reddy et al. Diagnostic Pathology  (2017) 12:45 Page 10 of 11Positive” tumors as “Positive” (Table 3). Besides, clone
SP142 yields a lower number of positive cells by IHC [22],
however, it is not clear which clone is most relevant to the
clinical outcome of cervical carcinomas. Further controlled
studies are required to elucidate the clone-outcome rela-
tionships in uterine cervical cancers. In a study regarding
uterine cervical cancers, the investigators have lumped
adencarcinomas and SCCs as a sinle group with no tumor
grading distiction [10]. There is, however, a general agree-
ment that a higher expression of PD-L1 is associated with a
poorer prognosis in uterine cervix, endometrium, and head
& neck caners [10, 33–35].
As recent trials have suggested tumors, with a genetic
basis for PD-1 ligand expression, are particularly sensitive
to anti-PD-1 immunotherapies. Howitt et al. have investi-
gated the status of genes encoding PD-1 ligands in cervical
SCC. They have found co-gain or co-amplification of
CD274 and PDCD1LG2, coding PD-L1 and PD-L2, in a
significant number of cervical SCCs [36]. In a recent study
of cervical SCC, patients with diffuse expression of PD-L1
were also found to have significantly worse disease-free
and disease-specific survival as compared to those with
only marginal PD-L1 expression [10].
Finally, the scoring algorithm in this study has been
adopted from the non-small cell lung cancers study [13],
noting that NSCLCs and cervical carcinomas are the same
entity. Our study has been carried out on a TMA with lit-
tle clinical information and no treatment data. Therefore,
the cutoff points for positivity for each therapeutic agent
should be determined after the clinical trials for cervical
cancers have been completed. Until then, the adopted
scoring is merely a reporting mean for pathologists in
which 50% as well as variable cutoffs are integrated into a
single system with addition of the IHC intensities.
Conclusions
This study has found a significant expression of PD-L1
in cervical malignancies, and no expression of PD-L1 in
normal cervix or benign cervical lesions. The current litera-
ture has identified potential genetic and immunopathogenic
rationales for PD-L1 expression in cervical cancers. The
findings in this study further support a role for the investi-
gation of anti-PD-L1/PD-1 immunotherapies for the treat-
ment of PD-L1-positive cervical tumors. In addition, our
adopted scoring system will help to identify different
responders to the immunotherapy as correlated with the
degree of PD-L1 expression. Thus, we recommend inter-
pretation and reporting of PD-L1 staining to include the
adopted score, percentage of the positive cells, and the in-
tensity of the reaction (e.g., Positive: 2a, 80%, 1+ or Low-
Positive: 1b, 10%, 3+) to facilitate a more solid correlation
with response to the treatment. Future clinical trials, based
on response to the targeted immunotherapies, may help to
further refine the proposed scoring system.Abbreviations
HPV: Human papillomavirus; IHC: Immunohistochemistry; LoPos: Low-
Positive; NSCLC: Non-small cell lung carcinomas; PD-1/PD-L1: Programmed
death-1/programmed death-ligand1; SCC: Squamous cell carcinoma;
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